Overview

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Status:
Approved for marketing
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib